Company intelligence / Profile preview

Jiangsu Shengdi

Lianyungang, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Shengdi is a core subsidiary of Jiangsu Hengrui Pharmaceuticals, responsible for much of the group's innovative drug R&D and manufacturing. It has successfully commercialized multiple innovative drugs in China, including the blockbuster PD-1 inhibitor AiRuiKa (camrelizumab) and the HER2-targeted small molecule AiRuiNi (pyrotinib). Its pipeline is one of the most extensive in China, with late-stage programs in ADCs, JAK inhibitors, and bispecific antibodies.

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibodyRecombinant fusion proteinPeptide
Industry: Pharma

Drug pipeline

1 asset

SDP2001

Preclinical

Partnerships

TG TherapeuticsMerck KGaAElevar TherapeuticsCrystalGenomics

Beyond the preview

Go deeper on Jiangsu Shengdi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Shengdi.

Explore the full profile